1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Celyad VP On IP Issues, Development Timelines For CAR-T Therapies

 
• By Lucie Ellis-Taitt

Georges Rawadi, vice president of business development and intellectual property at Celyad, talks to Scrip on the sidelines of the recent BIO-Europe Spring partnering conference in Barcelona about the company's pipeline of CAR-T therapies and recently resolved patent disputes for its technology.

Video interview
Celyad's George Rawadi talks to Scrip

Georges Rawadi, vice president of business development and intellectual property at Celyad SA, discusses the company's chimeric antigen receptors T- cells (CAR-T) pipeline, recently resolved IP issues and the firm's strategy for future clinical development.

On the sidelines of the recent BIO-Europe Spring partnering meeting, held in Barcelona, Mar. 20-22, Rawadi talks about how Celyad's technology will compete with other treatments coming through the immuno-oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.